As Representative Paul D. Ryan debated Vice President Joseph R. Biden Jr. on Thursday night, he sometimes seemed to be defending his own past budget and Medicare proposals as much as his running mate’s plans — sometimes in misleading ways.
When Mr. Ryan was defending his plan to reshape Medicare so future beneficiaries would receive fixed amounts of money to purchase private insurance or buy into the existing government program — a model for Mitt Romney’s proposal — he described his plan as “bipartisan,” and called it “a plan I put together with a prominent Democrat senator from Oregon.” But he failed to note that he later lost that Democrat’s support.
Read the full story: http://nyti.ms/Q5kuzP
Source: The New York Times
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More